PeopleBio Inc
PeopleBio, Inc., a biotech company, engages in developing diagnostics for protein misfolding diseases worldwide. Its Multimer Detection System technology uses capturing antibodies and epitope-overlapping detection antibodies for the detection of oligomers or multimers from monomers in protein-misfolding diseases. The company has strategic collaborations with Seoul National University Bundang Hosp… Read more
PeopleBio Inc (304840) - Net Assets
Latest net assets as of September 2025: ₩1.74 Billion KRW
Based on the latest financial reports, PeopleBio Inc (304840) has net assets worth ₩1.74 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩19.75 Billion) and total liabilities (₩18.01 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.74 Billion |
| % of Total Assets | 8.79% |
| Annual Growth Rate | 25.53% |
| 5-Year Change | -4.93% |
| 10-Year Change | N/A |
| Growth Volatility | 160.56 |
PeopleBio Inc - Net Assets Trend (2017–2024)
This chart illustrates how PeopleBio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PeopleBio Inc (2017–2024)
The table below shows the annual net assets of PeopleBio Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩8.39 Billion | -56.22% |
| 2023-12-31 | ₩19.17 Billion | +369.99% |
| 2022-12-31 | ₩4.08 Billion | -75.89% |
| 2021-12-31 | ₩16.92 Billion | +91.61% |
| 2020-12-31 | ₩8.83 Billion | +226.69% |
| 2019-12-31 | ₩2.70 Billion | -50.09% |
| 2018-12-31 | ₩5.41 Billion | +216.86% |
| 2017-12-31 | ₩1.71 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to PeopleBio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5903238538000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩10.61 Billion | 126.46% |
| Other Components | ₩77.01 Billion | 917.50% |
| Total Equity | ₩8.39 Billion | 100.00% |
PeopleBio Inc Competitors by Market Cap
The table below lists competitors of PeopleBio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Italtile Ltd
JSE:ITE
|
$5.72 Million |
|
Temas Resources Corp
OTCQB:TMASF
|
$5.72 Million |
|
Sego Resources Inc
V:SGZ
|
$5.73 Million |
|
Motio Ltd
AU:MXO
|
$5.73 Million |
|
VIQ Solutions Inc.
PINK:VQSSF
|
$5.72 Million |
|
Saville Resources Inc
V:SRE
|
$5.72 Million |
|
Alset AI Ventures Inc.
PINK:GPUSF
|
$5.72 Million |
|
CHINA GREEN AGRIC.DL-001
F:GR0A
|
$5.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PeopleBio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,171,364,660 to 8,393,143,900, a change of -10,778,220,760 (-56.2%).
- Net loss of 10,907,798,080 reduced equity.
- Other factors increased equity by 129,577,320.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-10.91 Billion | -129.96% |
| Other Changes | ₩129.58 Million | +1.54% |
| Total Change | ₩- | -56.22% |
Book Value vs Market Value Analysis
This analysis compares PeopleBio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.61x to 2.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩192.43 | ₩888.00 | x |
| 2018-12-31 | ₩548.02 | ₩888.00 | x |
| 2019-12-31 | ₩273.53 | ₩888.00 | x |
| 2020-12-31 | ₩788.57 | ₩888.00 | x |
| 2021-12-31 | ₩1028.34 | ₩888.00 | x |
| 2022-12-31 | ₩236.61 | ₩888.00 | x |
| 2023-12-31 | ₩911.55 | ₩888.00 | x |
| 2024-12-31 | ₩396.46 | ₩888.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PeopleBio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -129.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -292.32%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 3.23x
- Recent ROE (-129.96%) is above the historical average (-137.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -247.89% | 0.00% | 0.00x | 1.39x | ₩-4.41 Billion |
| 2018 | -65.49% | -6912.77% | 0.01x | 1.20x | ₩-4.09 Billion |
| 2019 | -148.07% | -447.04% | 0.21x | 1.61x | ₩-4.27 Billion |
| 2020 | -49.65% | -863.09% | 0.05x | 1.21x | ₩-5.27 Billion |
| 2021 | -27.80% | -814.96% | 0.01x | 3.04x | ₩-6.39 Billion |
| 2022 | -350.70% | -321.84% | 0.11x | 10.37x | ₩-14.71 Billion |
| 2023 | -83.61% | -359.99% | 0.16x | 1.44x | ₩-17.95 Billion |
| 2024 | -129.96% | -292.32% | 0.14x | 3.23x | ₩-11.75 Billion |
Industry Comparison
This section compares PeopleBio Inc's net assets metrics with peer companies in the Healthcare Equipment & Supplies industry.
Industry Context
- Industry: Healthcare Equipment & Supplies
- Average net assets among peers: $101,778,414,937
- Average return on equity (ROE) among peers: 9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PeopleBio Inc (304840) | ₩1.74 Billion | -247.89% | 10.37x | $5.72 Million |
| InBody Co.Ltd (041830) | $183.73 Billion | 18.52% | 0.11x | $208.16 Million |
| MEDIANA Co.Ltd (041920) | $34.91 Billion | 20.29% | 0.27x | $70.69 Million |
| Value Added Technology Co. Ltd (043150) | $349.29 Billion | 22.01% | 0.46x | $109.99 Million |
| MEKICS Co Ltd (058110) | $7.87 Billion | -24.74% | 1.89x | $14.44 Million |
| Meta Biomed Co. Ltd (059210) | $39.05 Billion | 3.02% | 0.38x | $50.83 Million |
| INFINITT Healthcare Co. Ltd (071200) | $77.28 Billion | 6.38% | 0.20x | $53.10 Million |
| i-SENS Inc (099190) | $118.81 Billion | 12.18% | 0.38x | $127.37 Million |
| Sewoon Medical Co. Ltd (100700) | $46.71 Billion | 7.88% | 0.18x | $34.07 Million |
| CU Medical Systems Inc (115480) | $58.36 Billion | 16.15% | 0.51x | $14.81 Million |